Global law firm Ashurst has advised LGC in relation to the sale of its drug development solutions (DDS) business to Alliance Pharma, a US-based bioanalytical contract research organisation and an Ampersand Capital Partners portfolio company. KKR has also become an equal shareholder in the combined business alongside Ampersand.
Keep up to date
Sign up to receive the latest legal developments, insights and news from Ashurst. By signing up, you agree to receive commercial messages from us. You may unsubscribe at any time.
Sign upAshurst LLP, New York, NY, is responsible for content in the US.